- Collaboration leverages OMass' OdyssionTM platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease
- OMass to receive $20 million upfront payment, with potential for more than $400 million in additional milestone payments, as well as tiered royalties on net sales
Oxford, United Kingdom - 2nd September 2025 - OMass Therapeutics ('OMass' or 'the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that it has entered into an exclusive collaboration and license agreement with Genentech, a member of the Roche Group, for the rights to develop and commercialize OMass' preclinical oral small molecule program for inflammatory bowel disease.
"Using our OdyssIONTM platform, we've been able to make significant progress on this novel first-in-class target with a differentiated mechanism of action in inflammatory bowel disease,"said Ros Deegan, CEO of OMass Therapeutics."Genentech brings a strong legacy of innovation in immunology and world class scientific expertise, making them an ideal partner for this program. We are delighted to be partnering with them and build on the progress we have made to date."
"There are nearly eight million people living with IBD who are in need of innovative treatment approaches,"said Boris L. Zaïtra, Head of Roche Corporate Business Development."Despite recent advancements, there is still a high unmet medical need which fuels our commitment to partnering with companies such as OMass Therapeutics focused on innovation to accelerate potentially transformative medicines and advance science."
Under the terms of the agreement, OMass will receive an upfront payment of $20 million, plus additional potential preclinical, development, commercial and net sales milestone payments of more than $400 million. OMass is also eligible for tiered royalties on net sales. Under the collaboration, OMass will lead the initial preclinical development of the program until candidate selection. Genentech will be responsible for clinical development, regulatory activities, manufacturing and commercialization.
-ENDS-
For further information, please contact:
| OMass Therapeutics | |
| Rosamond Deegan, Chief Executive Officer Email: ros.deegan@omass.com | |
ICR Healthcare (For media) | |
| Namrata Taak / Ashley Tapp Email: omass@icrhealthcare.com | |
Thrust Strategic Communications (ForIR) Renee Leck Email: renee@thrustsc.com |
About OMass Therapeutics
OMass Therapeutics is a biotechnology company discovering medicines against highly-validated target ecosystems, such as membrane proteins or intracellular complexes.
OdyssION, OMass' unique drug discovery platform, comprises next-generation native mass spectrometry with novel biochemistry techniques and custom chemistry to interrogate not just a drug target, but also the interaction of the target with its native ecosystem, separate from the confounding complexity of the cell. This unique approach results in cell-system fidelity with cell-free precision.
OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions. Its lead program is a best-in-class MC2 (melanocortin-2) receptor antagonist for the treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-dependent Cushing syndrome. The focus of the program has been to increase receptor residency time to make OMass' antagonists resistant to competition by the endogenous ligand, thereby avoiding loss of efficacy in the face of rising adrenocorticotropic hormone (ACTH) levels due to reductions in glucocorticoid supplementation for CAH or progression of Cushing's Syndrome.
Headquartered in Oxford, UK, OMass has raised over $160M (£129M) from a top-tier international investor syndicate including Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures and British Patient Capital.
To learn more, please visitwww.omass.com. Follow us onLinkedIn.
